IRCT20100228003449N29RecruitingPhase 2
Evaluating efficacy and safety of sofosbuvir/ ledipasvir in treatment of COVID-19
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 75 years (—)
- Sex
- All
Inclusion Criteria
- •Patients with highly suspected diagnosis of COVID-19
- •Patients with confirmed diagnosis of COVID-19
- •Patients who are candid for hospitalization
- •Patients who are candid for starting triple-drug combination
Exclusion Criteria
- •History of drug allergy
Investigators
Similar Trials
Unknown
Phase 3
Role of anti Hepatitis C drug (Sofosbuvir and Ribavirin)in Liver disease.CTRI/2017/11/010373ATCO PHARMACEUTICALS62
Recruiting
Phase 2
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60
Recruiting
Not Applicable
Evaluation of the efficacy of sofosbuvir and ledipasvir for Japanese hepatitis C patients: a prospective study in real-life settings.chronic hepatitis CJPRN-UMIN000019468Toranomon Hospital100
Recruiting
Not Applicable
Evaluation of the efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents: a prospective study in real life settings.cirrhotic and non cirrhotic patients with hepatitis C virusJPRN-UMIN000035713Toranomon Hospital150
Completed
Phase 3
Safety and efficacy of sofosbuvir in the moderate COVID19COVID19.Coronavirus infection, unspecifiedU07.1IRCT20180302038915N1Shahid Beheshti University of Medical Sciences50